Experimental cell therapy offers hope for kids with Hard-to-Treat autoimmune conditions
NCT ID NCT07439029
First seen Feb 28, 2026 · Last updated Apr 24, 2026 · Updated 11 times
Summary
This early-stage study tests a new cell therapy called YTS109 in 12 children aged 5 to 17 with severe autoimmune diseases like lupus and scleroderma that haven't responded to standard treatments. The therapy is given as a single IV infusion, and researchers will monitor safety and check if it helps control the disease. The goal is to see if this approach is safe enough to study further.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED VASCULITIS (AAV) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital of Fudan University
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.